No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.
Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.
The cancer startup develops novel immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer. The company is developing immuno-oncology drugs which could be combined with existing immunotherapies to enhance the efficiency of detecting and killing cancer cells.
Over the next five years, pharma giant, AstraZeneca will invest $90 million in India to improve the overall health outcomes in the country, by promoting innovation, skill development, and quality manufacturing.
The artificial intelligence (AI) based device called IDx-DR received US FDA approval for the screening of diabetic retinopathy- a common eye disease in diabetic patients that could lead to vision impairment and blindness.